Compare prices and buy CJC-1295 With DAC from 21 research peptide vendors - also called suppliers or sources. Updated daily.
A GHRH analog (CAS 446262-90-4, molecular formula C165H269N47O46) consisting of the tetrasubstituted GHRH(1-29) backbone plus a C-terminal lysine carrying a maleimidopropionamide group, the Drug Affinity Complex. The maleimide bonds covalently to cysteine 34 of serum albumin after injection, and its half-life in healthy adults was measured in days. Published human studies found growth hormone and IGF-1 elevated for days after a single injection with the natural pulse pattern preserved rather than flattened. It was developed by ConjuChem, which ended its clinical development, and is not FDA-approved. Distinct chemistry and a distinct evidence base from the No-DAC form, which FDA reported has no studies establishing pharmacological activity.
For research purposes only. Not medical advice.
CJC-1295 With DAC is the compound that originally carried the CJC-1295 name. ConjuChem Biotechnologies of Montreal made three maleimido derivatives of human GHRH(1-29) to overcome its very short half-life, and designated the one selected for development CJC-1295. Molecular formula C165H269N47O46, molecular weight 3647.95, CAS 446262-90-4.
Structurally it is the tetrasubstituted GHRH(1-29) backbone (D-alanine at position 2, glutamine at 8, alanine at 15, leucine at 27) plus a C-terminal lysine carrying an N-epsilon-3-maleimidopropionamide group. That appended group is the Drug Affinity Complex. The same backbone without it is indexed here as CJC-1295 No DAC, which acquired the name later, by subtraction.
The maleimide reacts with the free thiol on cysteine 34 of serum albumin, forming a covalent bond after injection, so the peptide circulates attached to albumin. Jetté and colleagues reported in Endocrinology in 2005 that CJC-1295 remained present in rat plasma beyond 72 hours and produced a fourfold larger growth hormone response than unmodified hGRF(1-29), measured as two-hour area under the curve. The authors credited albumin binding for the longer half-life. FDA noted in 2024 that direct evidence is lacking that the DAC group is what extends it, that showing the DAC form's half-life is longer than the no-DAC form's would be needed to support that, and that the backbone substitutions could also have contributed.
Both CJC-1295 rows are GHRH analogs, the family that also includes sermorelin and tesamorelin, while ipamorelin, GHRP-2 and hexarelin reach a comparable pituitary output through the ghrelin receptor instead. The evidence behind the two rows is not equivalent: reviewing both in 2024, FDA found published studies reporting the DAC form acts as a growth hormone secretagogue in rodents, and none establishing that the no-DAC free base or its acetate are pharmacologically active at all. FDA also noted that the reactive group could bind cysteine thiols on proteins other than albumin, a possible source of off-target effects.
Two 2006 papers in the Journal of Clinical Endocrinology and Metabolism carry nearly the entire human record. Teichman and colleagues ran two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults, lasting 28 and 49 days. A single subcutaneous injection raised mean plasma growth hormone twofold to tenfold for six days or more, and IGF-1 by 1.5-fold to threefold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. After repeat injections IGF-1 remained above baseline for up to 28 days.
Ionescu and Frohman asked whether continuous stimulation flattens the natural growth hormone pulses. It did not. A week after a single injection, pulse frequency and amplitude were unchanged. What moved was the trough, with basal growth hormone up 7.5-fold, mean levels up 46 percent and IGF-1 up 45 percent.
ConjuChem registered a Phase 2 trial in HIV-associated visceral obesity (NCT00267527) in December 2005. Two hours after an eleventh injection, one subject had a confirmed acute myocardial infarction and died about an hour later. The trial was terminated, ConjuChem withdrew the compound from development in 2006, and the data were never published, so FDA could reconstruct it only from contemporaneous press accounts.
In the healthy-adult studies, injection-site reactions were the most common adverse event and both Teichman trials reported frequent headache. In the single-dose trial, 30 percent of treated subjects had systemic vasodilatory reactions (flushing, warmth and transient hypotension). Nonclinical work FDA identified reported injection-site hemorrhage, inflammation and necrosis in rats and dogs on repeated injection, and genotoxic signals in mouse pituitary cells. FDA identified no carcinogenicity study.
CJC-1295 was placed in Category 2 of FDA's interim bulk drug substances policy, the designation for substances that may present significant safety risks. In September 2024, FDA removed it from Category 2 because the nominators had withdrawn their nominations. That did not end the review: FDA carried the substances to the Pharmacy Compounding Advisory Committee at its own discretion, and on December 4, 2024 the committee voted against every CJC-1295 substance it heard, the three DAC forms unanimously.
No CJC-1295 substance has a USP monograph or is a component of an approved drug. The World Anti-Doping Agency names CJC-1295 under S2.2.4, prohibited at all times.
FDA identified five distinct bulk drug substances under the CJC-1295 name and at least nine names in circulation for them, calling the inconsistency a safety risk in its own right. Three of the five are the DAC free base, acetate and trifluoroacetate.
PeptideScouter indexes CJC-1295 With DAC vials per milligram and verifies identity against its molecular formula rather than the product title.
DAC is the Drug Affinity Complex, a maleimidopropionamide group carried on a lysine appended to the C-terminus of the 29-residue GHRH analog. After injection the maleimide reacts with the free thiol on cysteine 34 of serum albumin and forms a covalent bond, so the peptide circulates attached to a long-lived carrier protein. In the published human studies the estimated half-life ran from 5.8 to 8.1 days. The developers credited albumin binding for that, but FDA noted in 2024 that direct evidence is lacking that the DAC group is what extends it, and that showing the DAC form's half-life is longer than the no-DAC form's would be needed to support that. That one group is the entire difference from CJC-1295 No DAC, and it is measurable: molecular formula C165H269N47O46 and molecular weight 3647.95 with the DAC, against C152H252N44O42 and 3367.95 without it. PeptideScouter indexes the two as separate rows, and vendors price them at different tiers.
ConjuChem Biotechnologies was running a Phase 2 trial of CJC-1295 in patients with HIV-associated visceral obesity, registered as NCT00267527 and started in December 2005. Two hours after an eleventh injection, one subject reported chest discomfort. An ECG confirmed an acute myocardial infarction and the subject died approximately one hour later. The attending physician's most likely explanation was that the patient had asymptomatic coronary artery disease with plaque rupture and occlusion. The trial was terminated and the company withdrew the compound from development in 2006. The study data were never published, and when FDA evaluated the substance in 2024 it could account for the episode only through contemporaneous press reports.
No CJC-1295 substance has a USP monograph and none is a component of an FDA-approved drug, which leaves the 503A bulks list as the only remaining route, and CJC-1295 is not on it. FDA placed the substance in Category 2 of its interim policy, the designation for substances that may present significant safety risks, and removed it from Category 2 in September 2024 after the nominators withdrew their nominations. FDA elected to bring the substances to the Pharmacy Compounding Advisory Committee regardless, and on December 4, 2024 the committee rejected all five, with CJC-1295 DAC free base, DAC acetate and DAC trifluoroacetate each voted down 0 in favor to 13 against. FDA also reported that no outsourcing facility has reported compounding a CJC-1295 product since 2020.
Yes. The World Anti-Doping Agency covers growth hormone releasing factors in section S2.2.4 of its Prohibited List and names CJC-1295 explicitly, alongside CJC-1293, sermorelin and tesamorelin. Section S2 substances are prohibited at all times, in and out of competition, and the entry is written to capture GHRH analogs as a class, so the DAC and no-DAC forms are both covered. Detection methods have been published for human and equine doping control, and mass spectrometry separates the two forms by mass.
PeptideScouter computes a per-milligram price only for vials sold by weight, so a listing recorded as a nasal spray is indexed and searchable but carries no per-milligram figure and will not appear in per-milligram comparisons or in the lowest-price line. The comparison would not be a fair one in any case: the human studies FDA reviewed all used subcutaneous injection, and FDA evaluated the substance for that route alone, so a milligram in a spray bottle and a milligram in a vial are not interchangeable quantities.
CJC-1295 With DAC is sold by 21 research peptide vendors indexed on PeptideScouter, with 30 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
18 of the 21 indexed vendors currently have CJC-1295 With DAC in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Peppy and Me currently lists CJC-1295 With DAC at $6.00/mg, the lowest listed price across 21 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $5.40/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 21 vendors listing CJC-1295 With DAC publish a PeptideScouter code, worth 5% to 20% off. Applied, the lowest effective price falls from $6.00/mg listed to $5.40/mg at Peppy and Me. Each vendor's code is shown beside its price in the table above.
CJC-1295 With DAC ranges from $6.00/mg to $23.98/mg across 30 listings from 21 research peptide vendors, normalized to USD per milligram and refreshed daily.
21 research peptide vendors currently list CJC-1295 With DAC on PeptideScouter, with 18 in stock right now. We track 30 listings across size and kit variants.
CJC-1295 With DAC's CAS Registry Number is 446262-90-4. It is also sold as CJC-1295 W/DAC, CJC-1295 with Dac, CJC-1295 (With DAC).
